Sk Biopharmaceuticals Co Ltd (326030) — Cash Flow Reinvestment Rate

Latest as of December 2025: 0.33x

Sk Biopharmaceuticals Co Ltd (326030) has a Cash Flow Reinvestment Rate of 0.33x as of December 2025, reinvesting ₩28.92 Billion (capex ₩26.55 Billion plus investments ₩-2.37 Billion) from operating cash flow of ₩87.00 Billion. Explore Sk Biopharmaceuticals Co Ltd capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.33x

(Capex + Investments) / Operating CF

Total Reinvested

₩28.92 Billion

Capex + Investments

Operating Cash Flow

₩87.00 Billion

KRW

Capital Expenditures

₩26.55 Billion

KRW

Sk Biopharmaceuticals Co Ltd Cash Flow Reinvestment Rate (2024–2025)

Historical reinvestment intensity for Sk Biopharmaceuticals Co Ltd across 2 annual periods. Also explore Sk Biopharmaceuticals Co Ltd assets under control for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Sk Biopharmaceuticals Co Ltd (2024–2025)

Year-by-year capital reinvestment analysis for Sk Biopharmaceuticals Co Ltd. For live market cap and broader valuation context, see 326030 stock market capitalisation.

Year	Reinvestment Rate	Total Reinvested (KRW)	Operating CF	Capex	YoY Change
2025	0.19x	₩33.88 Billion	₩176.33 Billion	₩29.51 Billion	▲ +7.7%
2024	0.18x	₩16.93 Billion	₩94.90 Billion	₩13.42 Billion	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow